Creegan & Nassoura Financial Group LLC Sells 925 Shares of Pfizer Inc. (NYSE:PFE)

Creegan & Nassoura Financial Group LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 1.0% in the fourth quarter, Holdings Channel reports. The firm owned 89,396 shares of the biopharmaceutical company’s stock after selling 925 shares during the quarter. Pfizer accounts for about 1.6% of Creegan & Nassoura Financial Group LLC’s portfolio, making the stock its 25th biggest position. Creegan & Nassoura Financial Group LLC’s holdings in Pfizer were worth $2,372,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Passumpsic Savings Bank grew its stake in shares of Pfizer by 8.4% during the 3rd quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company’s stock valued at $743,000 after purchasing an additional 1,998 shares during the period. Virtu Financial LLC purchased a new stake in shares of Pfizer in the 3rd quarter worth $1,499,000. Westside Investment Management Inc. raised its holdings in Pfizer by 7.7% in the 3rd quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 1,004 shares during the period. Diamant Asset Management Inc. grew its holdings in Pfizer by 8.4% during the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 660 shares during the period. Finally, Morse Asset Management Inc bought a new stake in Pfizer during the 3rd quarter worth approximately $2,649,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $22.13 on Monday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock’s fifty day moving average price is $24.88 and its 200-day moving average price is $26.15. The firm has a market cap of $125.50 billion, a P/E ratio of 15.69, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PFE. UBS Group dropped their price objective on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research note on Tuesday, April 8th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $31.07.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.